by The bioprocess validation market involves products and services used to validate biopharmaceutical manufacturing processes. Biopharmaceuticals or biologics are medicines manufactured or extracted from biological sources using biotechnology. They include vaccines, blood components, gene therapies, tissues, recombinant therapeutic proteins, and monoclonal antibodies. Validation is done to demonstrate that any process will consistently produce a product meeting its pre-determined specifications and quality attributes. It establishes documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes.
The global biopharmaceutical market has witnessed strong growth in recent years due to the increasing prevalence of chronic diseases. Biologics have revolutionized the treatment of cancer, autoimmune disorders, and other complex diseases. The development of novel biologic drugs and therapeutics has increased the need for validation of complex bioprocesses. Validation ensures the safety and efficacy of biopharmaceutical products. It helps companies comply with regulatory requirements. The bioprocess validation market offers products like consumables, equipment, and software & services used at various stages like facility, process, and equipment validation.
The global Bioprocess Validation Market is estimated to be valued at US$ 411.04 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends
One of the key trends in the bioprocess validation market is the increasing adoption of continuous bioprocessing. Compared to traditional batch processing methods, continuous bioprocessing provides advantages like higher product yields, minimal processing time, and reduction in validation requirements. It helps accelerate drug development and commercial production. Regulatory agencies also favor continuous operations due to advantages like real-time monitoring and tighter process control. Vendors are developing novel continuous bioprocessing technologies tailored for small molecules, vaccines, cell and gene therapies. Their integration with digital solutions like AI and IoT is advancing data-driven bioprocess validation approaches. This trend is expected to gain further ground in the coming years.
Porter’s Analysis
Threat of new entrants: The bioprocess validation market requires high capital investment and strict regulations, which reduces threat of new entrants.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over service providers and equipment suppliers in this market.
Bargaining power of suppliers: Few global suppliers exist for validation services and equipment, giving them strong bargaining power over buyers.
Threat of new substitutes: No close substitutes exist for bioprocess validation services and equipment used in pharmaceutical production.
Competitive rivalry: The market is moderately competitive with presence of global established players and some regional players.
Key Takeaways
The global Bioprocess Validation Market Demand is expected to witness high growth over the forecast period of 2024 to 2031. The global Bioprocess Validation Market is estimated to be valued at US$ 411.04 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031.
North America currently dominates the market due to presence of major pharmaceutical companies in the US and Canada. The region is expected to maintain its leading position throughout the forecast period driven by growing biopharmaceutical industry. Europe is the second leading region in the bioprocess validation market supported by expanding biotech sector and rising focus on biologic drugs in countries like Germany, France and the UK. The Asia Pacific region presents ample growth opportunities and is projected to be the fastest growing regional market between 2024 to 2031 due to growing generics industry in India and China.
Key players: Key players operating in the bioprocess validation market are GSK Plc (U.K.), TheraVida (U.S.), Revance (U.S.), NovaMedica. (Russia), Ulthera, Inc. (U.S.), DEMIRA e.V (Germany), Abbvie, Inc (U.S.), Fresh Tracks Therapeutics, Inc. (U.S.), Dr. August Wolff GmbH (Germany), Dermavant Sciences, Inc. (U.S.), Eirion Therapeutics, Inc (U.K.).
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
